The Blueprint Genetics Hyperlipidemia Panel is ideal tool for genetic analysis of patients with virtually any type of monogenic (Mendelian inheritance) dyslipidemia disorder. All classical familial hypercholesterolemia (FH) genes (APOB, LDLR, LDLRAP1 and PCSK9) as well as genes associated with other hyperlipidemias such as ‘type 3 hyperlipidemia’ (APOE), sitosterolemia (ABCG5, ABCG8), lipoprote...

Hyperlipoproteinemia can aggravate glomerulosclerosis and chronic tubulointerstitial (ti) damage in kidneys without primary immunologic disease. We evaluated whether the effect of hyperlipidemia on progression of renal damage differed between kidneys without preexisting glomerular disease and kidneys with mesangioproliferative glomerulonephritis and whether the renal actions of hyperlipidemia w...

CONTEXT Use of antiretroviral drugs, including protease inhibitors, for treatment of human immunodeficiency virus (HIV) infection has been anecdotally associated with hepatotoxicity, particularly in persons coinfected with hepatitis C or B virus. OBJECTIVES To ascertain if incidence of severe hepatotoxicity during antiretroviral therapy is similar for all antiretroviral drug combinations, and...

Hyperlipidemia is a condition of elevated lipid level in blood. Hyperlipidemia may be defined by serum total cholesterol >240mg/dL and/or LDL cholesterol >160mg/dL and/or total cholesterol: HDL ratio >5.7 and/or total triglycerides > 150mg/dL in adults. Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis related conditions like coronary heart disease (CHD), ischemic cerebrova...

The disabling pathophysiologic effects of lipid and neuroprotective effects of statins have recently been demonstrated for acute spinal cord injuries in animal models. This large scale population-based study aimed to investigate the effect hyperlipidemia and the use of statins in patients with lumbar spine injury. The National Health Insurance Research Database of Taiwan was used to identify pa...

Clinical outcome of diffuse large B-cell lymphoma (DLBCL) patients with hepatitis C virus (HCV) infection in the rituximab era remains unclear. The aim of the present study was to compare the clinical outcome, treatment response and hepatotoxicity in DLBCL patients who received rituximab containing immunochemotherapy that had HCV infection and tho...